Alan Schneider, MD
Cardiovascular Disease · Overland Park, KSNPI 1750331617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,265 and has fallen 80.4% since, to $248 in 2025.
Across 306 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Johnson & Johnson$992
- Novartis$590
- Pfizer$317
- Abbott$312
- Irhythm Technologies, Inc.$304
- plus $2K from 25 others
What the payments were for
- Consulting fees$200%
- Food & beverage$5,521100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 70 | $1,005 |
| Johnson & Johnson | 55 | $992 |
| Novartis | 40 | $590 |
| Pfizer | 21 | $317 |
| Abbott | 7 | $312 |
| Irhythm Technologies, Inc. | 12 | $304 |
| Boston Scientific | 13 | $268 |
| Boehringer Ingelheim | 17 | $268 |
| Merck | 9 | $162 |
| Sanofi-aventis U.S. LLC | 10 | $145 |
| Amarin Pharma, Inc. | 8 | $139 |
| Pacira Pharmaceuticals Incorporated | 1 | $121 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $119 |
| AstraZeneca | 6 | $103 |
| Novo Nordisk | 4 | $97 |
| E.r. Squibb & Sons, L.L.C. | 6 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $91 |
| Actelion Pharmaceuticals US, Inc. | 5 | $88 |
| Astellas Pharma US Inc | 2 | $47 |
| Philips North America LLC | 3 | $43 |
| Lemaitre Vascular, Inc. | 1 | $43 |
| Lantheus Medical Imaging, Inc. | 1 | $31 |
| Vital Connect, Inc | 1 | $27 |
| Lundbeck LLC | 1 | $23 |
| Sanofi | 1 | $20 |
| Z-medica, LLC | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Gilead | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$130
- EXPAREL$121
- ARCALYST$119
How this compares
$5,541 in reported general payments places this provider in the 75th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 482 | $456,448 |
| XareltoRivaroxaban | 235 | $227,705 |
| EntrestoSacubitril/Valsartan | 85 | $97,706 |
| Repatha SureclickEvolocumab | 112 | $93,577 |
| JardianceEmpagliflozin | 35 | $35,965 |
| Praluent PenAlirocumab | 35 | $26,721 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 26 | $9,698 |
| Ezetimibe | 289 | $6,393 |
| Ranolazine ErRanolazine | 41 | $5,724 |
| VascepaIcosapent Ethyl | 14 | $5,592 |
| Atorvastatin Calcium | 505 | $4,682 |
| Metoprolol Succinate | 389 | $4,599 |
| Potassium Chloride | 221 | $3,558 |
| Carvedilol | 460 | $3,264 |
| Losartan Potassium | 278 | $2,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $317 | $456,448482 claims |
| Johnson & JohnsonXarelto | $992 | $227,705235 claims |
| NovartisEntresto | $590 | $97,70685 claims |
| Boehringer IngelheimJardiance | $268 | $35,96535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Vasvi SinghOverland Park$405K
- Rachel SoslandOverland Park$33K
- Ahmed ElballatOverland Park$22K
- Paul NagerOverland Park$10K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
- Theodore PopeOverland Park$5K
- Stephen BloomOverland Park$5K
- James MarcumOverland Park$4K
- Bassem ChehabWichita$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.